Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Sarah Sammons; Noah S Kornblum; Kimberly L Blackwell

doi:10.1007/s11523-018-0614-x

Correction to: Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer

Target Oncol. 2019 Feb;14(1):13. doi: 10.1007/s11523-018-0614-x.

Authors

Sarah Sammons¹, Noah S Kornblum², Kimberly L Blackwell^{3

4}

Affiliations

¹ Duke University Medical Center, Durham, NC, USA.
² Montefiore Einstein Center for Cancer Care, Bronx, NY, USA.
³ Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA. [email protected].
⁴ Eli Lilly and Company, Indianapolis, IN, 46285, USA. [email protected].

Abstract

The article Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer, written by Sarah Sammons, Noah S. Kornblum and Kimberly L. Blackwell, was originally published electronically on the publisher's internet portal (currently SpringerLink).

Publication types

Published Erratum